[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dialysis-access-malfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dialysis-access-malfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100582868","six-month-response-rate-according-to-two-surgical-techniques-rotational-atherectomy-versus-angioplasty-to-treat-stenosis-of-vascular-accesses-in-hemodialysis-100582868",false,"NCT06868901","Six-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy Versus Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis.","Evaluation of the 6-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy vs. Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis. A Single-center, Randomized, Single-blind, Superiority-controlled Pilot Study.","ARSAV","Inclusion Criteria:\n\n* Hemodialysis patient on arteriovenous fistula (AVF) with re-stenosis defined on echodoppler by a combination of \\>50% venous lumen reduction with a systolic peak ratio \\>2 associated with either : i) an internal residual diameter of \\\u003C 2 mm, or ii) a flow reduction \\> 25% or a flow rate \\\u003C 500 ml\u002Fmin.\n* Patient with at least one history of angioplasty on his\u002Fher AVF at the same site.\n* Patient available for 6-month follow-up.\n* Patient with free and informed consent and signed consent form.\n* Patient affiliated with or benefiting from a health insurance plan.\n\nExclusion Criteria:\n\n* Patient with an intraoperative technical impossibility.\n* Patient with a septic complication.\n* Patient participating in another interventional trial.\n* Patient in an exclusion period determined by another study.\n* Patient under court protection, guardianship or curatorship.\n* Patient unable to give consent.\n* Patient for whom it is impossible to give informed information.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","A well-functioning hemodialysis vascular access is a decisive factor in the survival of hemodialysis patients, who have a high mortality rate. 85% of these hemodialysis patients, are treated via an arteriovenous fistula (AVF). However, the primary patency of AVFs at 1 year is 60%, mainly due to neointimal hyperplasia developing in the drainage vein, which leads to stenosis and, if left untreated, thrombosis of the AVF. Indeed, forty percent of hemodialysis patients require re-intervention on their vascular access within the year, due to stenosis on their AVF.\n\nTransluminal angioplasty (TLA) is currently used as first-line treatment for these stenoses but TLA itself causes vascular damage, with early recurrence of the stenosis in 50% of cases at 6 months, and necessitating repeated interventions.\n\nIn recent years several endovascular techniques have been developed to limit the risk of re-stenosis, none of which have produced significantly better results than simple TLA. Eliminating intimal hyperplasia using a minimally invasive endovascular technique, rather than crushing it with simple angioplasty, would improve restenosis-free survival in these patients.\n\nToday, endovascular rotational atherectomy techniques are available to improve the patency of angioplasty in the treatment of complex arterial lesions of the coronary arteries and lower limbs. The atherotome is a guide-mounted catheter with a small burr at its distal end, which resects the atheromatous plaque whereas angioplasty simply crushes it. Atherectomy is followed by drug-eluting balloon (DEB) angioplasty with paclitaxel release to limit restenosis through its anti-inflammatory and anti-proliferative activity. A few cases of rotational atherectomy for the treatment of calcified stenoses in saphenous vein coronary bypasses have been reported in the literature, with encouraging results. If AVF re-stenosis should occur, the intimal hyperplasia can be removed endovascularly, thereby limiting the risk of short-term iterative stenosis.\n\nThe aim of this study was to compare the 6-month re-stenosis rate with this technique (atherectomy + drug-eluting balloon) versus standard angioplasty + drug-eluting balloon for the treatment of restenosis of hemodialysis vascular accesses.",[27,28,29],"Hemodialysis Complication","Dialysis Access Malfunction","Stenosis",[31,32,33,34,35,36],"Arteriovascular fistula","Angioplasty","Balloon","Atherectomy","Fistula","Re-stenosis","NOT_YET_RECRUITING","2025-03-05",{"date":40,"type":41},"2025-03-11","ACTUAL",{"date":43,"type":21},"2025-03-01",{"date":45,"type":21},"2027-12-01",{"name":47,"class":48},"Centre Hospitalier Universitaire de Nīmes","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100558617","phase-3-randomised-clinical-trial-comparing-drug-coated-balloon-to-plain-balloon-for-all-peripheral-avf-stenosis-100558617","NCT06553443","Randomised Clinical Trial Comparing Drug-coated Balloon to Plain Balloon for All Peripheral AVF Stenosis","RANGER","Inclusion Criteria:\n\n1. Failing AVF with at least 1 AVF stenosis presenting with any clinical, physiological or haemodynamic abnormalities. Both de novo and recurrent stenosis are accepted.\n2. AVF has been used successfully for at least 1 month (non-mature AVF are not allowed).\n3. Less than 30% residual stenosis after angioplasty.\n4. ≥ 21 years old\n5. Informed and valid consent given.\n\nExclusion Criteria:\n\n1. Thrombosed AVFs\n2. Haemodynamically significant central vein stenosis\n3. Target lesion not treatable with the available sizes of drug eluting balloon (up to 8mm)\n4. Contraindication to antiplatelet therapy\n5. Coagulopathy or thrombocytopenia that cannot be managed adequately with periprocedural transfusion.\n6. Allergy \u002F contraindication to paclitaxel.\n7. Acute infection over proposed puncture site.\n8. Women who are breastfeeding, pregnant \\* or planning on becoming pregnant during study.\n9. Participant with medical conditions, which in the opinion of the investigator may cause noncompliance with protocol.\n10. Currently participating in an investigational drug, biologic or device trial that may have an impact on the dialysis access or previous enrolment in this study.","21 Years",{"count":58,"type":21},94,[60],"PHASE3","To compare the access circuit primary patency after Ranger drug-coated balloon angioplasty of arteriovenous fistula (AVF) stenosis with that after conventional balloon angioplasty",[63,64,28],"Arteriovenous Fistula","Arteriovenous Fistula Stenosis",[66,67],"drug-coated balloon","access circuit patency","RECRUITING","2024-08-11",{"date":71,"type":41},"2024-08-14",{"date":73,"type":41},"2024-01-04",{"date":75,"type":21},"2029-12-31",{"name":77,"class":48},"Singapore General Hospital",1]